Description: Pherecydes Pharma SA develops antibacterial treatments based on the use of bacteriophage viruses or phages. It develops a portfolio of therapeutics, such as anti-Staphylococcus aureusphages for the treatment of bone/joint and diabetic foot ulcer infections; anti-Pseudomonas aeruginosa phages for the treatment of complicated urinary tract infections; and anti-Escherichia coli phages for the treatment of respiratory tract infections. The company was founded in 2006 and is based in Romainville, France.
Home Page: www.pherecydes-pharma.com
102 avenue Gaston Roussel
Romainville,
93230
France
Phone:
33 1 48 40 65 35
Officers
| Name | Title |
|---|---|
| Mr. Didier Hoch | Chairman & CEO |
| Mr. Thibaut du Fayet | COO & Deputy CEO |
| Ms. Flavie Pouillot | Head of R&D |
Exchange: PA
Country: FR
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.816 |
| Price-to-Sales TTM: | 11.0233 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 20 |